Fjarde Ap-fonden’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Fjarde Ap-fonden’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-200,416	Closed	-$138K	–	568
2020 Q4	$138K	Hold	200,416	–	–	﹤0.01%	563
2020 Q3	$451K	Hold	200,416	–	–	﹤0.01%	598
2020 Q2	$717K	Hold	200,416	–	–	0.01%	594
2020 Q1	$762K	Hold	200,416	–	–	0.01%	584
2019 Q4	$603K	Buy	+200,416	New	+$521K	0.01%	611

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Fjarde Ap-fonden's BMY.RT Position: Q1 2021 in Review

Fjarde Ap-fonden sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 200,416 shares — an estimated $138K sold.

Fjarde Ap-fonden first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $762K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Fjarde Ap-fonden reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Fjarde Ap-fonden sold 200,416 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $138K.
Fjarde Ap-fonden first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Fjarde Ap-fonden's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $762K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Fjarde Ap-fonden's 13F filing for Q1 2021, filed 17 May 2021.